Wechselwirkungen · Keytruda
KEYTRUDA 25 mg/mL concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 15
HOS-131794 · Präparat HOS-097138
The use of systemic corticosteroids or immunosuppressants before starting pembrolizumab should be avoided because of their potential interference with the pharmacodynamic activity and efficacy of pembrolizumab. However, systemic corticosteroids or other immunosuppressants can be used after starting pembrolizumab to treat immune-mediated adverse reactions (see section 4.4). Corticosteroids can also be used as premedication, when pembrolizumab is used in combination with chemotherapy, as antiemetic prophylaxis and/or to alleviate chemotherapy-related adverse reactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T16:10:00Z · SHA-256 e087d75948ee6d7e0436cc4d9426ed91824e992a89f4481a4ea0ddb3e3ee3588 · Passage 33e873ecc0e8e816826559577c4ffb70556d8a30e6ec96bad532f570fa77c6c9 · Zeichen 214–787 im Abschnitt